Titan Medical
Titan Medical
TMDIF
OTC
0.90
USD
0.00%
About
Titan Medical Inc. is a medical technology company. The Company is focused on the development and commercialization of surgical technologies for single access robotic assisted surgery (RAS) requiring only a single patient access point. It has integrated technology into the Enos surgical system with the purpose of enhancing the robotic assisted surgical experience for surgeons.
The Enos surgeon workstation includes a three dimensional (3D) high-definition display to provide a crucial balance of surgical immersion and situational awareness in the operating room. The display is mounted to the ergonomic workstation with a natural handle interface designed to deliver and support comfortable surgical posture, even during long procedures.
The Company's multi-articulated instruments bring fluid flexibility and strength to position the end effectors for grasping, suturing, cutting and coagulation..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 61.7K |
| Three Month Average Volume | 908.2K |
| High Low | |
| Fifty-Two Week High | 0.14531 USD |
| Fifty-Two Week Low | 0.03633 USD |
| Fifty-Two Week High Date | 12 Sep 2023 |
| Fifty-Two Week Low Date | 30 Aug 2024 |
| Price and Volume | |
| Current Price | 0.04359 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | 14.25% |
| Thirteen Week Relative Price Change | 4.06% |
| Twenty-Six Week Relative Price Change | -34.84% |
| Fifty-Two Week Relative Price Change | -69.32% |
| Year-to-Date Relative Price Change | -32.67% |
| Price Change | |
| One Day Price Change | 20.00% |
| Thirteen Week Price Change | 9.09% |
| Twenty-Six Week Price Change | -29.41% |
| Five Day Price Change | 20.00% |
| Fifty-Two Week Price Change | -64.71% |
| Year-to-Date Price Change | -25.00% |
| Month-to-Date Price Change | 14.29% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.04114 USD |
| Book Value Per Share (Most Recent Quarter) | 0.02346 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.04114 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.02346 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.01802 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.14794 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.0079 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -72656.1976 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -72656.1976 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | 0.05834 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.04348 USD |
| Normalized (Last Fiscal Year) | 0.07957 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | 0.06027 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.04342 USD |
| Including Extraordinary Items (Last Fiscal Year) | 0.05834 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.04348 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.06485 USD |
| Cash Per Share (Most Recent Quarter) | 0.03351 USD |
| Cash Flow Per Share (Last Fiscal Year) | 0.0599 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.04101 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.0531 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -189 |
| Cash Flow Revenue (Trailing Twelve Months) | -672 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -528.42% |
| Pretax Margin (Last Fiscal Year) | 39.57% |
| Pretax Margin (5 Year) | -201.84% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | 35.00% |
| Operating Margin (Trailing Twelve Months) | -604.84% |
| Operating Margin (5 Year) | -218.57% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | 39.43% |
| Net Profit Margin (Trailing Twelve Months) | -531.26% |
| Net Profit Margin (5 Year) | -201.89% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -26.42% |
| Tangible Book Value (5 Year) | 9.46% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -100.00% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -94.47% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -4.11% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -12.72% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -109.57% |
| EPS Change (Trailing Twelve Months) | 64.79% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | 1 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -3,778,040 |
| Net Debt (Last Fiscal Year) | -8,392,650 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 0 |
| Price to Sales (Trailing Twelve Months) | 5 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | 1 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 73 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 1 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 18 |
| Long Term Debt to Equity (Most Recent Quarter) | 22 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | 0.00% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | 0 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 3 |
| Current Ratio (Most Recent Quarter) | 4 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | 6.0M |
| Free Cash Flow (Trailing Twelve Months) | -8,608,530 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 28 |
| Total Debt to Equity (Most Recent Quarter) | 40 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | 87.56% |
| Return on Assets (Trailing Twelve Months) | -58.12% |
| Return on Assets (5 Year) | -113.26% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | 857.87% |
| Return on Equity (Trailing Twelve Months) | -96.22% |
| Return on Equity (5 Year) | -1,046.25% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | 365.95% |
| Return on Investment (Trailing Twelve Months) | -82.14% |
| Return on Investment (5 Year) | -793.56% |